The news: Obesity drug developer Kailera Therapeutics raised $625 million in its Thursday IPO, the largest US biopharma listing since 2021. It’s now secured more than $1 billion in total funding.

• Kailera priced shares at $16, the top of its $14 to $16 range, and sold 39 million shares. The offering drew double-digit oversubscription, per Bloomberg.
• The biotech is developing four GLP-1-based weight loss drugs, including a weekly shot and a daily pill, which are both in late-stage trials.

Why it matters: Eli Lilly and Novo Nordisk dominate the obesity drug market, but Kailera’s IPO underscores investor confidence and the strength and durability of demand—even as the field grows crowded.

• Novo’s Wegovy (injectable and pill) and Lilly’s Zepbound (injectable) and Foundayo (pill) are the only obesity drugs currently on the market, with Lilly holding a 60% market share.
• The obesity drug market is forecast to reach between $100 billion and more than $150 billion by 2030.
• Other biotechs, including Structure Therapeutics—which recently posted weight loss pill results rivaling Novo and Lilly—are vying to enter the market, alongside pharma companies such as AstraZeneca, Merck, Pfizer, and Roche.

Demand for GLP-1s for weight loss continues to grow. 42% of overweight Americans who are not currently taking a GLP-1 for weight loss say they’re likely to start one in 2026, per a January Sunlight.com survey. For context, by the end of 2025, 13% of US adults were using a GLP-1 for weight loss, per Zappi.

Implications for obesity drugmakers: Kailera’s record IPO signals that the obesity market is entering its most competitive phase yet and moving away from traditional pharma launch timelines. New, well-funded competitors and more big pharma players are increasing pressure on speed to market and commercialization strategy.

In this competitive landscape, drugmakers will need to launch faster and engage patients earlier—long before they enter a doctor’s office or telehealth platform—as success shifts to capturing volume in a crowded market.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.